Oncopeptides AB (publ)

LSE:0RN4 Stock Report

Market Cap: SEK 404.1m

Oncopeptides Valuation

Is 0RN4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RN4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 5.78
Fair Value
67.5% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: 0RN4 (SEK1.88) is trading below our estimate of fair value (SEK5.78)

Significantly Below Fair Value: 0RN4 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RN4?

Key metric: As 0RN4 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0RN4. This is calculated by dividing 0RN4's market cap by their current revenue.
What is 0RN4's PS Ratio?
PS Ratio12.8x
SalesSEK 31.65m
Market CapSEK 404.12m

Price to Sales Ratio vs Peers

How does 0RN4's PS Ratio compare to its peers?

The above table shows the PS ratio for 0RN4 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.3x
OPTI OptiBiotix Health
33.1xn/aUK£18.9m
APTA Aptamer Group
6.1xn/aUK£7.4m
TRX Tissue Regenix Group
1xn/aUK£23.2m
PBX ProBiotix Health
5.2xn/aUK£11.1m
0RN4 Oncopeptides
12.8x60.1%SEK 404.1m

Price-To-Sales vs Peers: 0RN4 is expensive based on its Price-To-Sales Ratio (12.8x) compared to the peer average (11.3x).

Price to Sales Ratio vs Industry

How does 0RN4's PS Ratio compare vs other companies in the GB Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
2x3.9%US$1.76b
OXB Oxford Biomedica
2.4x16.5%US$389.40m
TRX Tissue Regenix Group
1xn/aUS$30.70m
AREC Arecor Therapeutics
2.9x-11.6%US$19.03m
0RN4 12.8xIndustry Avg. 7.5xNo. of Companies8PS020406080100+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0RN4 is expensive based on its Price-To-Sales Ratio (12.8x) compared to the European Biotechs industry average (7.5x).

Price to Sales Ratio vs Fair Ratio

What is 0RN4's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RN4 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.8x
Fair PS Ratio18x

Price-To-Sales vs Fair Ratio: 0RN4 is good value based on its Price-To-Sales Ratio (12.8x) compared to the estimated Fair Price-To-Sales Ratio (18x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RN4 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 1.88
SEK 2.50
+33.0%
37.1%SEK 3.80SEK 1.70n/a3
May ’26SEK 1.95
SEK 2.50
+27.9%
37.1%SEK 3.80SEK 1.70n/a3
Apr ’26SEK 1.66
SEK 2.50
+50.6%
37.1%SEK 3.80SEK 1.70n/a3
Mar ’26SEK 1.60
SEK 2.57
+60.2%
39.8%SEK 4.00SEK 1.70n/a3
Feb ’26SEK 1.57
SEK 2.73
+74.3%
34.9%SEK 4.00SEK 1.70n/a3
Jan ’26SEK 1.56
SEK 2.73
+75.2%
34.9%SEK 4.00SEK 1.70n/a3
Dec ’25SEK 1.64
SEK 2.73
+66.5%
34.9%SEK 4.00SEK 1.70n/a3
Nov ’25SEK 2.08
SEK 4.33
+108.1%
33.1%SEK 6.00SEK 2.50n/a3
Oct ’25SEK 2.12
SEK 4.33
+104.4%
33.1%SEK 6.00SEK 2.50n/a3
Sep ’25SEK 2.17
SEK 5.77
+165.4%
16.5%SEK 6.80SEK 4.50n/a3
Aug ’25SEK 2.41
SEK 6.10
+153.1%
8.8%SEK 6.80SEK 5.50n/a3
Jul ’25SEK 2.75
SEK 6.10
+122.2%
8.8%SEK 6.80SEK 5.50n/a3
Jun ’25SEK 3.13
SEK 6.10
+95.2%
8.8%SEK 6.80SEK 5.50n/a3
May ’25SEK 3.01
SEK 6.10
+103.0%
8.8%SEK 6.80SEK 5.50SEK 1.953
Apr ’25SEK 6.50
SEK 6.15
-5.4%
10.6%SEK 6.80SEK 5.50SEK 1.662
Mar ’25SEK 6.35
SEK 6.15
-3.2%
10.6%SEK 6.80SEK 5.50SEK 1.602
Feb ’25SEK 6.84
SEK 6.90
+0.9%
1.4%SEK 7.00SEK 6.80SEK 1.572
Jan ’25SEK 7.64
SEK 6.90
-9.7%
1.4%SEK 7.00SEK 6.80SEK 1.562
Dec ’24SEK 8.59
SEK 6.90
-19.6%
1.4%SEK 7.00SEK 6.80SEK 1.642
Nov ’24SEK 6.97
SEK 9.25
+32.6%
8.1%SEK 10.00SEK 8.50SEK 2.082
Oct ’24SEK 8.84
SEK 9.25
+4.6%
8.1%SEK 10.00SEK 8.50SEK 2.122
Sep ’24SEK 7.81
SEK 9.25
+18.5%
8.1%SEK 10.00SEK 8.50SEK 2.172
Aug ’24SEK 8.05
SEK 14.50
+80.1%
3.4%SEK 15.00SEK 14.00SEK 2.412
Jul ’24SEK 8.66
SEK 14.50
+67.5%
3.4%SEK 15.00SEK 14.00SEK 2.752
Jun ’24SEK 7.89
SEK 14.50
+83.7%
3.4%SEK 15.00SEK 14.00SEK 3.132
May ’24SEK 11.23
SEK 18.00
+60.3%
22.2%SEK 22.00SEK 14.00SEK 3.012
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
SEK 2.50
Fair Value
24.9% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/08 23:34
End of Day Share Price 2025/05/08 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncopeptides AB (publ) is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdCarnegie Investment Bank AB
Patrik LingDNB Markets
Peter WelfordJefferies LLC